drugset / Trial / NCT06693336
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2
Recruiting
42 enrolled
ToLymph Inc.
Mayo Clinic, Rochester, MN · collabUniversity Health Network, Toronto · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
Timeline
- Start
- 2024-11-18
- Primary completion
- 2026-11-18
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SMS001 | Unknown | — | — |